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Abstract 
Treatment of in vitro cultured Ehrlich ascites carcinoma cells with cisplatin, daunomycin, doxorubicin, cytosine arabinoside, 3’-fluorodeoxythymid- 
ine, colchicine and vincristine in cytostatically effective concentrations results in significantly increased levels of the small stress protein, hsp25, as 
analyzed by immunoblotting. However, no induction of hsp25 could be detected after treatment of the tumour cells with 5-fluorouracil, aminopterin, 
amethopterin, mithramycine and cyclophosphamide. None of these cytostatic drugs induces hsp70. 
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1. Introduction 
Exposure of cells to heat shock and various chemicals 
results in synthesis and accumulation of different classes 
of stress proteins, which also correlates with the develop- 
ment of a transient state of cross-resistance to other 
stress inducing agents (for reviews see [l-3]). Generation 
of resistance is one of the problems in cancer therapy. 
Besides metabolic degradation of cytostatics and devel- 
opment of multi-drug resistance of cells by activation of 
the mdr-1 gene, stress proteins may also be involved in 
acquired resistance of tumor cells against anti-neoplastic 
treatments. In a previous paper [4] we reported on the 
induction of the small stress protein, hsp25, in Ehrlich 
ascites carcinoma cells by cisplatin. Because of the possi- 
ble clinical importance of this finding, we tested further 
anticancer drugs which interfere with different biochem- 
ical pathways or act on molecular targets involved in cell 
proliferation, for their ability to induce the mammalian 
stress proteins, hsp25 and hsp70. 
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Abbrevations: DMEM, Dulbeccos’s modified Eagle’s medium; EAC, 
Ehrlich ascites carcinoma; FCS, fetal calf serum; hsc70, constitutively 
expressed 70 kDa heat shock protein; hsp, heat shock, or more gener- 
ally, stress inducible proteins (hsp25 murine, hsp27 human low molec- 
ular stress protein; hsp70 inducible stress protein of the high molecular 
family); SDS-PAGE, sodium dodecylsulfate polyacrylamide gel elec- 
trophoresis. 
2. Experimental 
2.1. Cultivation of EAC cells 
Ehrlich ascites carcinoma cells (EAC cells) were cultured in 5 ml 
DMEM supplemented with 15% heat inactivated FCS in a humified 
CO2 incubator. 2. lo6 cells per 20 ml flask were seeded in the assays with 
drugs which were applied at final concentrations (see Fig. 1) that re- 
sulted in 100% inhibition of cell proliferation. In the controls without 
drugs, starting with 1.10’ cells, the increase in cell number during the 
total incubation time of 72 h was about 20-fold. According to this 
protocoll, the final number of cells at the end of incubations was about 
2. lo6 both in the controls and in the assays with drugs. Cells were 
incubated at 37°C at first for 48 h without (controls) or in the presence 
of the respective drug. Thereafter, drugs were washed out and then the 
cells cultured for a further 24 h period for recovery before being proc- 
essed for hsp25 and hsp70 detection by immunoblotting. Heat shock 
induction of hsp25 and hsp70 was performed by incubation of EAC 
cells for 1 h at 41.0°C, followed by a 4 h recovery period at 36.8”C and 
a second heat shock for 2 h at 42.5’C. 
2.2. Western blot analysis of hsp25 and hsp70 
EAC cells were lysed in SDS sample buffer (50 mM Tris-HCl, pH 
6.8, 3% (v/v) glycerol, 5% (v/v)/3-mercaptoethanol, 0.1% (w/v) Bromo- 
phenol blue) by boiling for 5 min. Proteins (50 pg per lane, equivalent 
to 5. lo5 cells) were separated by SDS-PAGE [5]. After electrophoresis, 
Western blotting was performed as described [6,7]. Anti-hsp25 antibod- 
ies were raised in rabbits against mouse hsp25 as described [6,7]. Anti- 
hsp70 monoclonal antibodies, specific for the inducible form (SPA- 
810AP; clone C92F3A-5), and anti-hsc70 antibodies for the constitutive 
form (SPA-815; clone lB5) were purchased from StressGen Biotech. 
Corp., Vie., Canada. 
2.3. Anticancer drugs 
Amethopterin (methotrexate), aminopterin, cisplatin (cis-diam- 
minedichloroplatinum), cyclophosphamide, daunomycin (daunorubi- 
tin), doxorubicin (adriablastin, adriamycin), mithramycine and vin- 
cristine were from Sigma, colchicine from Fluka, cytosine arabinoside 
from Ferak, 5-fluorouracil from La Roche; 3’-fluorodeoxythymidine 
was synthexised and supplied by Dr. M. v. Janta-Lipinsky (Max- 
Delbriick-Center, Berlin). 
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3. Results 
Cultured EAC cells in the exponentially growing 
phase contain hsc70, the constitutive form of the hsp70 
stress protein family (data not shown), but they do not 
express hsp25 and hsp70 in measurable amounts (Fig. 1, 
lane 1). Exposure of EAC cells to heat shock (see section 
2) leads to significant induction of hsp25 and hsp70 (Fig. 
1, lanes 2 and 15), while the amount of hsc70 is not 
increased above the constitutive level (not shown). Cis- 
platin, doxorubicin, daunomycin, cytosine arabinoside, 
3’-fluorodeoxythymidine, colchicine and vincristine in- 
duce significant expression of hsp25 at concentrations 
required to achieve complete inhibition of cell prolifera- 
tion (Fig. 1, lanes 3-9). However, no induction of hsp25 
could be detected for 5-fluorouracil, aminopterin, 
amethopterin (methotrexate) and mithramycine. Cyclo- 
phosphamide, which exerts its cytostatic effect after in 
vivo transformation, does not induce hsp25 in in vitro 
cultured EAC cells. Furthermore, hsp25 could not be 
dedected in EAC cells after exposure to 1.0 Gy 6oCo 
generated gamma rays (5 Gy/min dose rate) as applied 
in human cancer radiotherapy (S. Oesterreich and G. 
Erzgraber, data not shown). None of the tested cytostatic 
substances induces hsp70 (Fig. 1). 
4. Discussion 
We have shown in the present communication that the 
response of EAC cells to various anticancer drugs differs 
with respect to expression of hsp25 and hsp70. Drugs 
that induce hsp25 do not induce expression of hsp70. 
Possibly, the genes of the two heat shock proteins are the 
subject of different types of regulation of their activity in 
response to various chemical agents, which possibly gen- 
erate different activating processes. 
A further important point of the present investigation 
is the finding that certain drugs induce hsp25, but others 
do not. This raises the question about correlations be- 
tween the mode of biochemical actions resulting in cyto- 
static effects and the stimulation of hsp25 expression. It 
is apparent that effective drugs interfere directly with 
processes at the level of DNA replication in the S phase 
(cisplatin, doxorubicin, daunomycin, cytosine arabi- 
noside, 3’-fluorodeoxythymidine) or with the microtu- 
bule system arresting cells in the M phase of the cell cycle 
(colchicine, vincristine), whereas drugs which act cyto- 
statically by interfering with nucleotide metabolism in 
the G, phase (5-fluorouracil, aminopterin, amethop- 
terin) do not induce hsp25. Cisplatin, as well as doxoru- 
bicin and daunomycin, form adducts with DNA result- 
ing in inhibition of template properties of DNA. Cyto- 
sine arabinoside interferes with DNA replication after 
phosphorylation to the corresponding triphosphate as a 
competitive inhibitor of DNA polymerase with respect 
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Fig. 1. Stress protein response of in vitro cultured Ehrlich ascites carci- 
noma cells to heat shock and to anticancer drugs at concentrations 
resulting in about 100% inhibition of cell proliferation. Analysis by 
immunoblotting. Lanes: 1, control (untreated cells); 2, heat shocked 
cells (see section 2); 3, 2. 10m6 M cisplatin; 4, 3. lo-’ M doxorubicin; 
5, 3. lo-’ M daunomycin; 6, 1. 10m6 M cytosine arabinoside; 7, 1. 10e4 
M 3’-fluorodeoxythymidine; 8, 1. lo-’ M colchicine; 9, 1. 10m5 M vin- 
&tine; 10, 1. lo-’ M 5-fluorouracil; 11, 5. lo-* M aminopterin; 12, 
5.10-* M methotrexate; 13, 1.10e6 M mithramycine; 14, 
5. 10e6 M cyclophosphamide; 15, heat shock (as in lane 2). 
to dCTP. 3’-Fluorodeoxythymidine inhibits elongation 
of the nascent DNA chain at the template by preventing 
the formation of phosphodiester bonds. Following the 
rules mentioned above, mithramycine, which binds non- 
covalently and non-intercalatively to GC base pairs of 
DNA, should also properly induce hsp25. That it does 
not do so is makes it an exception to the proposed sug- 
gestion. As shown, cytostatics acting in the G, phase do 
not induce hsp25. 5-Fluorouracil inhibits conversion of 
deoxyuridylic acid (dUMP) to deoxythymidylic acid 
(dCMP) by thymidylate synthase (EC 2.1.1.45), and both 
aminopterin and amethopterin are efficient as inhibitors 
of dihydrofolate reductase (EC 1.5.1.3). Studies are 
under way to examine activation of heat shock elements 
and transcription factors in cells treated with various 
cancerostatics. 
A third aspect to be discussed concerns correlations 
between the synthesis of the small mammalian stress 
protein and the development of resistance against anti- 
cancer drugs. For instance, Ciocca et al. [8] have shown 
that human breast cancer cells expressing high levels of 
hsp27 after heat shock are more resistant o doxorubicin 
treatment han non-stressed cells, while heat shock did 
not confer cross-resistance to other anticancer drugs 
such as 5-fluorouracil, methotrexate, colchicine and cis- 
platin. Resistance to vincristine-inflicted cytotoxicity and 
microtubule destruction in heat shocked rat brain tu- 
mour cells has been described by Lee et al. [9]. In exper- 
iments with Chinese hamster cells, Hahn et al. [IO] found 
that thermotolerant cells were resistant o doxorubicin, 
and, in contrast to the findings of Ciocca et al. [8], also 
to cisplatin. Huot et al. [ll] described acquired ther- 
moresistance of Chinese hamster cells following transfec- 
tion with a plasmid containing the structural gene of 
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human hsp27. Cells over-expressing hsp27 were also 
found to be more chemoresistant in response to doxoru- 
bicin, daunorubicin, colchicine, and vincristine, but not 
to 5-fluorouracil. Oesterreich et al. [12] found that 
human breast cancer cells, over-expressing hsp27 after 
transfection with hsp27cDNA displayed elevated resis- 
tance to doxorubicin. When these findings of other au- 
thors and the results of our studies are considered it is 
apparent that thermoresistant cells are also chemore- 
sistant against such cancerostatics (doxorubicin, dauno- 
mycin, cisplatin, colchicine, vincristine) which induce 
hsp25/hsp27, but not against drugs which do not increase 
hsp25 (54uorouraci1, methotrexate). The induction of 
stress proteins is considered to be correlated with ther- 
motolerance and also transient states of cross-tolerance 
to cytostatic drugs. This may have considerable clinical 
importance in the treatment of tumors by chemotherapy, 
irradiation and hyperthermia as clinical studies on the 
combination of various therapeutic modalities become 
more frequent. 
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